MEDCL
MEDINCELL
Stock Euronext / Paris – Stock Market Prices, News & Analysis
MedinCell is a pharmaceutical company developing long-acting injectable treatments for various diseases.
MEDINCELL
MEDCL
MedinCell is a pharmaceutical company developing long-acting injectable treatments for various diseases.
Price history of MEDINCELL
Price history of MEDINCELL
Performance & Momentum
Medincell posts strong H1 results, preps Olanzapine LAI launch
Medincell reported consolidated first-half 2025 results showing encouraging growth driven by the strong performance of its UZEDY product. The company anticipates a major catalyst with the expected 2026 launch of its extended-release olanzapine treatment, developed in partnership with Teva Pharmaceuticals, which recently filed for FDA approval in the US. This dynamic backdrop, supported by the Shift to Growth strategy, presents favorable prospects for Medincell and could boost its share price on Euronext Paris.
Strategic Analysis
MEDINCELL • 2026
MedinCell positions itself as an innovative player in the French pharmaceutical sector, specializing in the development of long-acting injectable treatments. Its business model relies on the valuation of proprietary technologies that enhance therapeutic efficacy by providing extended dosage solutions, thereby targeting an increasing clinical need.
- Differentiating long-acting release technology with strong potential for medical adoption
- Innovative portfolio likely to generate strategic pharmaceutical partnerships
- Gradual market validation with robust stock performance over the medium and long term
- Dependence on the success of clinical trials and regulatory approvals
- High risk associated with the development phase and still limited commercialization
The current momentum is particularly strong, driven by sustained positive dynamics over several years that reflect market confidence in the potential of its innovations. This favorable trend invites consideration of MedinCell as a growth opportunity in the French biotech sector, while remaining vigilant to key upcoming regulatory milestones.
Similar stocks to MEDINCELL
Recent News
MEDINCELL
Medincell Strengthens Outlook with Key November Moves
4 months agoIn November 2025, Medincell boosts its presence in the financial and pharmaceutical sectors. The company will participate in the Jefferies London Healthcare Conference, where its management will provide a corporate overview. Additionally, Dr. Grace Kim’s role has expanded to Chief Strategy Officer, U.S. Finance, reflecting a strategic push to grow capital in the U.S. market. Medincell has also been added to the MSCI World Small Cap Index, a major benchmark featuring the most liquid and best-performing small caps across 23 developed markets, potentially attracting more international investors. These developments come amid a strong stock performance, with shares up 75% year-to-date, driven by pipeline advancements and increased exposure to global financial markets.
Medincell Joins MSCI Small Cap, Boosts US Strategy
5 months agoMedincell, an innovator in long-acting injectable therapies, has been selected for inclusion in the MSCI World Small Cap index, highlighting its growth and liquidity in developed markets. Concurrently, the company has strengthened its team by appointing Dr. Grace Kim as Chief Strategy Officer, responsible for US finance, enhancing its capital-raising capabilities in the US. These developments come as partner Teva prepares to file for US approval of Olanzapine LAI, a key product, by the end of 2025. This positive momentum is expected to support Medincell's valuation on Euronext Paris while attracting international investor interest.
Take control
of your investments
Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.
- Real-time multi-portfolio tracking
- AI analysis of your positions
- Counter your cognitive biases
